Table 17Key resolution outcomes in studies comparing nadolol and propranolol

Author, Year
Comparison Groups (n)
Quality		Age, months

Type		LocationMethods and Measures of Resolution/ResponseResolution OutcomesRebound Growth/Recurrence, n (%)
Pope et al, 2012101
G1: Nadolol suspension up to 4 mg/kg/day (10)
G2: Propranolol maximum dose 2–3 mg/kg/day (historical group) (9)

Quality: Poor		Age, mean±SD
G1: 4.1 ± 2.23
G2: 4.8 ± 1.92

Type, n:
Superficial and deep
G1: 6
G2: 9

Deep
G1: 4
G2: 0		G1+G2: multiple
  • Serial photographs and clinical assessment using 100-mm visual analog scale (VAS); blinded assessors
    (-): 100% worsening
    0: no change
    (+): 100% shrinkage where 5 mm represented 10% change
Percentage IH shrinkage, mean ± SD
G1: 97 ± 3.05%
G2: 86 ± 14.82%
G1 vs.G2: p< 0.008		NR

G = groups; IH = infantile hemangioma; kg = kilograms; mm = millimeter; mg = milligram; n = number; NR = not reported; SD = standard deviation

From: Results

Cover of Diagnosis and Management of Infantile Hemangioma
Diagnosis and Management of Infantile Hemangioma [Internet].
Comparative Effectiveness Reviews, No. 168.
Chinnadurai S, Snyder K, Sathe N, et al.
Copyright Notice

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.